Zeidler H
Z Rheumatol. 1987 Mar-Apr;46(2):59-66.
The efficiency of sulphasalazine (SASP) as a long-acting antirheumatic drug for rheumatoid arthritis is now well established by placebo-controlled studies and comparative trials with injectable gold and D-penicillamin. Early treatment effect and better tolerance suggest the use of SASP especially for early treatment of rheumatoid arthritis. Severe and advanced disease, in which gold and/or D-penicillamin were not effective or toxic, may also be treated with SASP. Open questions are the effect on the radiological progression and the differential indication to antimalarials, oral gold and methotrexat. Positive results of two placebo-controlled studies in ankylosing spondylitis for the first time open the perspective of a long-acting antiphlogistic therapy in this disease. Further open trials observed promising treatment effects of SASP in reactive and juvenile rheumatoid arthritis. Therefore, future clinical studies have to establish indication, benefit-risk-relation and treatment modalities also in these rheumatic disorders.
通过安慰剂对照研究以及与注射用金制剂和青霉胺的对比试验，柳氮磺胺吡啶（SASP）作为类风湿关节炎长效抗风湿药物的有效性现已得到充分证实。早期治疗效果及更好的耐受性表明SASP尤其适用于类风湿关节炎的早期治疗。对于金制剂和/或青霉胺无效或有毒性的重症及晚期疾病，也可用SASP进行治疗。关于其对放射学进展的影响以及与抗疟药、口服金制剂和甲氨蝶呤的鉴别指征仍存在疑问。两项针对强直性脊柱炎的安慰剂对照研究取得了阳性结果，首次为该病长效抗炎治疗开辟了前景。进一步的开放性试验观察到SASP在反应性和青少年类风湿关节炎中具有有前景的治疗效果。因此，未来的临床研究还必须确定这些风湿性疾病的适应证、效益风险关系及治疗方式。
